Filter By Category
Archives
Share on -
DABRAFENIB
Generic Name: DABRAFENIB
ABSTRACT -
Dabrafenib is a BRAF kinase inhibitor used in selected BRAF V600 mutation-positive cancers, often in combination with a MEK inhibitor depending on indication. This document is not a prescribing guide.
DOSAGE -
- Follow the approved label for the cancer type and mutation status.
- Common adult dosing is oral twice-daily administration in labeled regimens, with product-specific dose modifications.
- Combination with trametinib or other therapy must follow approved labeling.
SIDE EEFECTS -
- Fever, fatigue, chills, headache, nausea, vomiting, diarrhea, rash, arthralgia, or cough may occur.
- Skin lesions, hyperkeratosis, hemorrhage, hyperglycemia, ocular events, and cardiac effects may occur.
- Secondary malignancies and severe febrile reactions are important risks.
ALLERGIC REACTIONS -
- Immediate rash, hives, itching, flushing, or generalized skin reaction
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, shortness of breath, or severe dizziness
- Severe hypotension, collapse, or anaphylaxis requires emergency care
- Any suspected allergy should be documented and reported to future healthcare providers
DRUG INTERACTIONS-
- Strong CYP3A4/CYP2C8 inhibitors or inducers may alter exposure.
- Dabrafenib can affect exposure to hormonal contraceptives and other CYP substrates.
- Concomitant QT-risk or anticancer agents require review.
PREAUTONS–
- Confirm BRAF mutation before treatment.
- Monitor fever, skin exams, cardiac function, glucose, ocular symptoms, and liver tests.
- Use contraception and avoid pregnancy during and after treatment as directed by label.
WARNINGS –
- Serious fever, bleeding, cardiomyopathy, ocular toxicity, severe skin reactions, or new cancers require urgent evaluation.
- Do not use in wild-type BRAF tumors unless specifically indicated.
- Keep out of reach of children.
Share on -
. Developed by